June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Regulatory T cell levels and cytokine production in active non-infectious uveitis: in vitro effect of anti-TNF-α, dexamethasone, and cyclosporine
Author Affiliations & Notes
  • Blanca Molins
    Ophthalmology, Hospital Clinic Barcelona, Barcelona, Spain
    Ophthalmology, Fundacio Clinic Recerca Biomedica, IDIBAPS, Barcelona, Spain
  • Victor Llorens
    Ophthalmology, Hospital Clinic Barcelona, Barcelona, Spain
  • Marina Mesquida
    Ophthalmology, Hospital Clinic Barcelona, Barcelona, Spain
  • Laura Pelegrin
    Ophthalmology, Hospital Clinic Barcelona, Barcelona, Spain
  • Alfredo Adan Civera
    Ophthalmology, Hospital Clinic Barcelona, Barcelona, Spain
  • Footnotes
    Commercial Relationships Blanca Molins, None; Victor Llorens, None; Marina Mesquida, None; Laura Pelegrin, None; Alfredo Adan Civera, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2029. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Blanca Molins, Victor Llorens, Marina Mesquida, Laura Pelegrin, Alfredo Adan Civera; Regulatory T cell levels and cytokine production in active non-infectious uveitis: in vitro effect of anti-TNF-α, dexamethasone, and cyclosporine. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2029.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate circulating regulatory T-cell (Treg) levels and cytokine production by peripheral blood mononuclear cells (PBMC) in patients with active non-infectious uveitis and to evaluate the effect of in vitro treatment with infliximab, dexamethasone, and cyclosporine on Treg levels and cytokine production in PBMC from uveitis and healthy subjects.

Methods: We included 12 patients with active non-infectious uveitis from Hospital Clinic of Barcelona (Spain) and 11 age-matched healthy subjects. PBMC were obtained by Ficoll gradient and cultured for 24 h in the presence or absence of dexamethasone (0.1-1x10-6M), cyclosporine (100-200 ng/ml), and infliximab (5-20 μg/ml). Treg (CD3+CD4+Foxp3+CD25highCD127low) levels in PBMC were determined by flow cytometry using the following fluorochrome-labeled monoclonal antibodies: AF700-CD3, Fitc-CD4, APC-CD25, PeCy7-CD127, and PE-Foxp3 (eBiosciences). Supernatants of cultured PBMC were collected and IL-10 and TNF-α levels were measured by ELISA (R&D Duoset).

Results: No significant differences were observed in Treg levels between uveitis patients and control subjects. However, PBMC from uveitis patients produced significantly higher amounts of TNF-α (20.3 ±8.9 pg/mL vs. 6.9 ± 3.4 pg/ml, P<0.05) and lower amounts of IL-10 (12.7± 3.9 pg/mL vs. 20.0±6.0 pg/mL, P<0.05). In vitro treatment with infliximab and cyclosporine did not modulate the levels of CD3+CD4+Foxp3+, CD3+CD4+CD25high, CD3+CD4+Foxp3+CD25high, and CD3+CD4+Foxp3CD25highCD127low in both groups. However, dexamethasone treatment significantly reduced CD25high in CD3+CD4+ cells from uveitis patients, decreasing Treg levels. Furthermore, dexamethasone also increased in a dose-dependent manner CD127 expression in CD3+CD4+ cells in both uveitis and control subjects, further reducing Treg levels. On the other hand, dexamethasone and infliximab treatment significantly reduced TNF-α production in PBMC from both groups without affecting IL-10 production.

Conclusions: Our results suggest that TNF-α and IL-10 production by PBMC rather than altered Treg levels are associated with active uveitis and that in vitro treatment with infliximab and dexamethasone lower the inflammatory response without increasing Treg levels.

Keywords: 746 uveitis-clinical/animal model • 555 immunomodulation/immunoregulation • 490 cytokines/chemokines  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×